



October 26, 2017

## ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017

BURLINGTON, Mass.--(BUSINESS WIRE)-- [ArQule](#), Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2017 before the market opens on Thursday, November 9, 2017. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update.

The live webcast can be accessed in the "Investors and Media" section of our website, [www.arqule.com](http://www.arqule.com), under "[Events & Presentations](#)." You may also listen to the call by dialing (877) 868-1831 within the U.S. or (914) 495-8595 outside the U.S. A replay will be available two hours after the completion of the call and can be accessed in the "Investors & Media" section of our website, [www.arqule.com](http://www.arqule.com), under "[Events and Presentations](#)."

### About ArQule

[ArQule](#) is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule's mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making [ArQule](#) a leader among companies our size in precision medicine. ArQule's proprietary pipeline includes: Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology indications; ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in a phase 1/2 company sponsored study for Overgrowth Diseases, in a phase 1 study for ultra-rare Proteus syndrome conducted by the National Institutes of Health (NIH), as well as in multiple oncology indications; ARQ 751, a next generation AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; and ARQ 761, a  $\beta$ -lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center. In addition, we have advanced ARQ 531, an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, in phase 1 for patients with B-cell malignancies refractory to other therapeutic options. ArQule's current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company's proprietary library of compounds. You can follow us on [Twitter](#) and [LinkedIn](#).

View source version on [businesswire.com](http://businesswire.com): <http://www.businesswire.com/news/home/20171026005070/en/>

ArQule, Inc.  
Dawn Schottlandt, 781-994-0300  
Vice President, Investor Relations/  
Corp. Communications  
[www.arqule.com](http://www.arqule.com)

Source: ArQule, Inc.

News Provided by Acquire Media